Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
Tevogen Bio (Nasdaq: TVGN) CEO Ryan Saadi congratulates Robert F. Kennedy Jr. on his confirmation as Secretary of Health and Human Services. The company emphasizes that Secretary Kennedy's goals for accessible and affordable healthcare align with Tevogen Bio's business model of delivering cost-efficient healthcare solutions.
As a clinical-stage specialty immunotherapy biotech company, Tevogen Bio aims to continue developing specialized immunotherapies for Americans both domestically and abroad. Dr. Saadi expresses enthusiasm about working with Secretary Kennedy to advance evidence-based medicine and create an equitable healthcare system in the U.S.
Tevogen Bio (Nasdaq: TVGN) il CEO Ryan Saadi congratula Robert F. Kennedy Jr. per la sua nomina a Segretario della Salute e dei Servizi Umani. L'azienda sottolinea che gli obiettivi del Segretario Kennedy per una sanità accessibile e conveniente sono in linea con il modello di business di Tevogen Bio, che si impegna a fornire soluzioni sanitarie economiche.
In quanto azienda biotecnologica specializzata in immunoterapia in fase clinica, Tevogen Bio mira a continuare a sviluppare immunoterapie specializzate per gli americani sia a livello nazionale che internazionale. Il Dr. Saadi esprime entusiasmo nel collaborare con il Segretario Kennedy per promuovere la medicina basata sull'evidenza e creare un sistema sanitario equo negli Stati Uniti.
Tevogen Bio (Nasdaq: TVGN) el CEO Ryan Saadi felicita a Robert F. Kennedy Jr. por su confirmación como Secretario de Salud y Servicios Humanos. La empresa enfatiza que los objetivos del Secretario Kennedy en cuanto a la atención médica accesible y asequible están en línea con el modelo de negocio de Tevogen Bio, que se dedica a ofrecer soluciones de salud rentables.
Como una empresa biotecnológica especializada en inmunoterapia en etapa clínica, Tevogen Bio tiene como objetivo continuar desarrollando inmunoterapias especializadas para los estadounidenses tanto a nivel nacional como internacional. El Dr. Saadi expresa su entusiasmo por trabajar con el Secretario Kennedy para avanzar en la medicina basada en la evidencia y crear un sistema de salud equitativo en EE.UU.
Tevogen Bio (Nasdaq: TVGN)의 CEO 라이언 사디가 로버트 F. 케네디 주니어의 보건복지부 장관 임명을 축하합니다. 회사는 케네디 장관의 접근 가능하고 저렴한 의료 목표가 Tevogen Bio의 비용 효율적인 의료 솔루션 제공 비즈니스 모델과 일치한다고 강조합니다.
임상 단계의 전문 면역 요법 생명공학 회사인 Tevogen Bio는 국내외 미국인을 위한 전문 면역 요법 개발을 계속할 것을 목표로 하고 있습니다. 사디 박사는 케네디 장관과 협력하여 근거 기반 의학을 발전시키고 미국에서 공정한 의료 시스템을 만드는 것에 대한 열정을 표현합니다.
Tevogen Bio (Nasdaq: TVGN) le PDG Ryan Saadi félicite Robert F. Kennedy Jr. pour sa confirmation en tant que secrétaire à la Santé et aux Services sociaux. L'entreprise souligne que les objectifs du secrétaire Kennedy en matière de soins de santé accessibles et abordables s'alignent sur le modèle économique de Tevogen Bio, qui consiste à fournir des solutions de santé rentables.
En tant qu'entreprise biopharmaceutique spécialisée en immunothérapie en phase clinique, Tevogen Bio vise à continuer de développer des immunothérapies spécialisées pour les Américains, tant sur le plan national qu'international. Le Dr Saadi exprime son enthousiasme à l'idée de travailler avec le secrétaire Kennedy pour faire progresser la médecine fondée sur des preuves et créer un système de santé équitable aux États-Unis.
Tevogen Bio (Nasdaq: TVGN) CEO Ryan Saadi gratuliert Robert F. Kennedy Jr. zu seiner Bestätigung als Gesundheits- und Sozialminister. Das Unternehmen betont, dass die Ziele von Minister Kennedy hinsichtlich einer zugänglichen und erschwinglichen Gesundheitsversorgung mit dem Geschäftsmodell von Tevogen Bio übereinstimmen, das kosteneffiziente Gesundheitslösungen anbietet.
Als biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Immuntherapien spezialisiert hat, zielt Tevogen Bio darauf ab, weiterhin spezialisierte Immuntherapien für Amerikaner sowohl im Inland als auch im Ausland zu entwickeln. Dr. Saadi äußert seine Begeisterung über die Zusammenarbeit mit Minister Kennedy, um evidenzbasierte Medizin voranzutreiben und ein gerechtes Gesundheitssystem in den USA zu schaffen.
- None.
- None.
WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, congratulates Robert F. Kennedy Jr.’s as he begins his role at the head of Health and Human Services.
Secretary Kennedy and the administration’s collective goal of achieving accessibility to affordable healthcare in the U.S. aligns with Tevogen Bio’s business model, which focuses on delivering cost-efficient and value driven healthcare solutions. With the evolving landscape of drug development, Tevogen Bio leadership hopes to continue its positive progress toward developing specialized immunotherapies for Americans at home and serving abroad.
“I extend my sincere congratulations to Secretary Kennedy on his confirmation and look forward to his leadership in advancing evidence-based medicine and alleviating access barriers to life-saving innovations,” said Dr. Saadi. He continued, “His commitment to affordability and efficiency aligns with Tevogen Bio’s core principle, and I look forward to working with him to advance an equitable and sustainable healthcare system in the U.S.”
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
How does Secretary Kennedy's appointment align with Tevogen Bio's (TVGNW) business strategy?
What is Tevogen Bio's (TVGNW) current development focus in 2025?
What are Tevogen Bio's (TVGNW) stated goals regarding healthcare accessibility?
How does Tevogen Bio (TVGNW) plan to work with the new HHS Secretary?
